Can the premises of the altered homeostatic theory permit improvement in the prevention of ischemic heart disease?

Medical Hypotheses

Volumn 60, Issue 1, 2003, Pages 12-25

  Hellstrom, H Richard ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

ADRENERGIC SYSTEM; ARTICLE; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY; EPICARDIUM; HEART PROTECTION; HOMEOSTASIS; ISCHEMIC HEART DISEASE; LIPID METABOLISM; METABOLIC DISORDER; MOLECULAR BIOLOGY; PRIORITY JOURNAL; VASOSPASM;

EID: 0037222516     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(02)00328-6     Document Type: Article

References (145)

1. Hellstrom H. R. The altered homeostatic theory: A holistic approach to multiple diseases, including atherosclerosis, ischemic diseases, and hypertension. Med Hypotheses 1999; 53: 194-199.
2. Krut L. H. On the statins, correcting plasma lipid levels, and preventing the clinical sequelae of atherosclerotic coronary heart disease. Am J Cardiol 1998; 81: 1045-1046.
3. Brown M. S., Goldstein J. L. Heart attacks: Gone with the century? Science 1996; 272: 629.
4. Parthasarathy S., Santanam N., Ramachandran S., Meilhac L. Oxidants and antioxidants in atherogenesis: An appraisal. J Lipid Res 1999; 40: 2143-2157.
5. Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
6. Hellstrom H. R. The spasm of resistance vessel concept of ischemic heart disease and other ischemic diseases. Med Hypotheses 1990; 33: 31-41.
7. Hellstrom H. R. Evidence in support of the spasm of resistance vessel concept of ischemic heart disease: An update in 1993. Med Hypotheses 1993; 41: 11-22.
8. Hellstrom H. R. New evidence for the spasm of resistance vessel concept of ischemic diseases. Med Hypotheses 1999; 53: 200-209.
9. Mcfarlane R. G Haemostasis. In: R. Biggs (ed). Human Blood Coagulation, Haemostasis and Thrombosis. Oxford: Blackwell Scientific Publications, 1976: 608-654.
10. Lip G. Y. Hypertension and the prothrombotic state. J Hum Hypertens 2000; 14: 687-690.
11. Lefkowitz R. J., Hoffman B. B., Taylor P. Neurotransmission: The autonomic and somatic motor nervous systems. In: J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, A. G. Gilman (eds). The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: 105-139.
12. von Känel R., Dimsdale J. E. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol 2000; 65: 357-369.
13. Mehta J. L., Saldeen T. G. P., Rand K. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998; 31: 1217-1225.
14. Hingorani A. D., Cross J., Kharbanda R. K. et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999.
15. Hansen P. R. Inflammatory alterations in the myocardial microcirculation. J Mol Cell Cardiol 1998; 30: 2555-2559.
16. Reaven G. M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities - The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
17. Hjermann I. The metabolic cardiovascular syndrome: Syndrome X, Reaven's syndrome, insulin resistance syndrome, atherothrombogenic syndrome. J Cardiovasc Pharmacol 1992; 20(suppl 8): S5-S10.
18. Campbell W. B., Halushka P. V. Lipid-derived autacoids: Eicosanoids and platelet-activating factor. In: J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996: 601-616.
19. 2 biosynthesis. J Biol Chem 1989; 264: 141-150.
20. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-2012.
21. Loscalzo J., Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87-104.
22. Celermajer D. S. Endothelial dysfunction: Does it matter? Is it reversible?. J Am Coll Cardiol 1997; 30: 325-333.
23. Steinberg H. O., Bayazeed B., Hook G., Johnson A., Cronin J., Baron A. D. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997; 96: 3287-3293.
24. Zeiher A. M., Schächinger V., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92: 1094-1100.
25. Taddei S., Galetta F., Virdis A. et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation 2000; 101: 2896-2901.
26. Ghiadoni L., Donald A. E., Cropley M. et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000; 102: 2473-2478.
27. Kanani P. M., Sinkey C. A., Browning R. L., Allaman M., Knapp H. R., Haynes W. G. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 1999; 100: 1161-1168.
28. Fichtlscherer S., Rosenberger G., Walter D. H., Breuer S., Dimmeler S., Zeiher A. M. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006.
29. Capaldo B., Guardasole V., Pardo F. et al. Abnormal vascular reactivity in growth hormone deficiency. Circulation 2001; 103: 520-524.
30. Dupuis J., Tardif J.-C., Cernacek P., Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999; 99: 3227-3233.
31. Khalil M. E., Basher A. W., Brown E. J., Jr., Alhaddad I. A. A remarkable medical story: Benefits of angiotensin-converting enzyme inhibitors in cardiac patients. J Am Coll Cardiol 2001; 37: 1757-1764.
32. Chambers J. C., Ueland P. M., Obeid O. A., Wrigley J., Refsum H., Kooner J. S. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102: 2479-2483.
33. Title L. M., Cummings P. M., Giddens K., Genest J. J., Jr., Nassar B. A. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000; 36: 758-765.
34. Sherman D. L., Keaney J. F., Jr., Biegelsen E. S., Duffy S. J., Coffman J. D., Vita J. A. Pharmacological concentrations of ascorbic acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension 2000; 35: 936-941.
35. Kugiyama K., Motoyama T., Doi H. et al. Improvement of endothelial vasomotor dysfunction by treatment with α-tocopherol in patients with high remnant lipoproteins levels. J Am Coll Cardiol 1999; 33: 1512-1518.
36. Moreno H., Jr., Chalon S., Urae A. et al. Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. Am J Physiol 1998; 275: H1040-H1045.
37. Goodfellow J., Bellamy M. F., Ramsey M. W., Jones C. J., Lewis M. J. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000; 35: 265-270.
38. Duffy S. J., Biegelsen E. S., Holbrook M. et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001; 103: 2799-2804.
39. Duffy S. J., Keaney J. F., Jr., Holbrook M. et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104: 151-156.
40. New G., Duffy S. J., Harper R. W., Meredith I. T. Long-term oestrogen therapy is associated with improved endothelium-dependent vasodilation in the forearm resistance circulation of biological males. Clin Exp Pharmacol Physiol 2000; 27: 25-33.
41. Hashimoto M., Kim S., Eto M. et al. Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery. Am J Cardiol 2001; 88: 1457-1459.
42. Stein J. H., Keevil J. G., Wiebe D. A., Aeschlimann S., Folts J. D. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999; 100: 1050-1055.
43. Duffy S. J., Vita J. A., Holbrook M., Swerdloff P. L., Keaney J. F., Jr. Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 1084-1089.
44. Freedman J. E., Parker C. III, Li L. et al. Select flavonoids and whole juice from purple grapes inhibit platelet function and enhance nitric oxide release. Circulation 2001; 103: 2792-2798.
45. Oparil S. Introduction: Blood pressure and beyond: Treating the cardiovascular disease complex with perindopril. Am J Cardiol 2001; 88(suppl 7A): li-2i.
46. Panza J. A., Epstein S. E., Quyyumi A. A. Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity. N Engl J Med 1991; 325: 986-990.
47. Chrousos G. P., Gold P. W. The concepts of stress and stress system disorders: Overview of physical and behavioral homeostasis. JAMA 1992; 267: 1244-1252.
48. McEwen B. S. Protective and damaging effects of stress mediators. N Engl J Med 1998; 338: 171-179.
49. Remme W. J. The sympathetic nervous system and ischaemic heart disease. Eur Heart J 1998; 19(suppl F): F62-F71.
50. Schomig A., Richardt G. Cardiac sympathetic activity in myocardial ischemia: Release and effects of noradrenaline. Basic Res Cardiol 85(suppl. 1): 9-30.
51. Bühler F. R. Cardiovascular risk factors - An integrated sympathetic viewpoint. Schweiz Med Wochenschr 1991; 121: 1793-1802.
52. Julius S. The defense reaction: A common denominator of coronary risk and blood pressure in neurogenic hypertension. Clin Exp Hypertens 1995; 17: 375-386.
53. Boone J. L. Stress and hypertension. Prim Care 1991; 18: 623-649.
54. Åblad B., Björkman J. A., Gustafsson D., Hansson G., Östlund-Lindqvist A. M., Pettersson K. The role of sympathetic activity in atherogenesis: Effects of β-blockade. Am Heart J 1988; 116: 322-327.
55. Julius S., Gudbrandsson T. Early association of sympathetic overactivity, hypertension, insulin resistance, and coronary risk. J Cardiovasc Pharmacol 1992; 20(suppl. 8): S40-S48.
56. Sleight P. Smoking and hypertension. Clin Exp Hypertens 1993; 15: 1181-1192.
57. Kuhn F. E., Johnson M. N., Gillis R. A., Visner M. S., Schaer G. L. Effect of cocaine on the coronary circulation and systemic hemodynamics in dogs. J Am Coll Cardiol 1990; 16: 1481-1491.
58. 2 synthesis after the cold pressor test in patients with angina at rest. Circulation 1986; 73: 409-417.
59. Dakak N., Quyyumi A. A., Eisenhofer G., Goldstein D. S., Cannon R. O. Sympathetically mediated effects of mental stress on the cardiac microcirculation of patients with coronary artery disease. Am J Cardiol 1995; 76: 125-130.
60. Patel P., Mendall M. A., Carrington D. et al. Association of Helicobactor pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-714.
61. Meier C. R., Derby L. E., Jick S. S., Vasilakis C., Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-431.
62. Ridker P. M. Inflammation, infection, and cardiovascular risk: How good is the clinical evidence? Circulation 1998; 97: 1671-1674.
63. Aller M. A., Arias J. L., Lorente L., Nava M. P., Durán H. J., Arias J. Neuro-immune-endocrine functional system and vascular pathology. Med Hypotheses 2001; 57: 561-569.
64. Ross R. Atherosclerosis: A defense mechanism gone awry. Am J Pathol 1993; 143: 987-1002.
65. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
66. Appels A. Inflammation and the mental state before an acute coronary event. Ann Med 1999; 31(suppl. 1): 41-44.
67. Liuzzo G., Buffon A., Biasucci L. M. et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 1998; 98: 2370-2376.
68. Yudkin J. S., Kumari M., Humphries S. E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-214.
69. Fernández-Real J.-M., Vayreda M., Richart C. et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men. J Clin Endocrinol Metab 2001; 86: 1154-1159.
70. Kahaleh M. B., Fan P. S. Effects of cytokines on the production of endothelin by endothelial cells. Clin Exp Rheumatol 1997; 15: 163-167.
71. Osuka K., Suzuki Y., Tanazawa T. et al. Interleukin-6 and development of vasospasm after subarachnoid hemorrhage. Acta Neurochir 1998; 140: 943-951.
72. Frölich M., Boeing H., Imhof A. et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care 2000; 23: 1835-1839.
73. Cardillo C., Kilcoyne C. M., Cannon R. O. I. Increased activity of endogenous endothelin in patients with hypercholesterolemia. J Am Coll Cardiol 2000; 36: 1483-1488.
74. Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
75. Oskarsson H. J., Heistad D. D. Oxidative stress produced by angiotensin too: Implications for hypertension and vascular injury. Circulation 1997; 95: 557-559.
76. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342: 145-153.
77. Yusuf S., Gerstein H., Hoogwerf B. et al. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
78. O'Driscoll G., Green D., Maiorana A., Stanton K., Colreavy F., Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes. J Am Coll Cardiol 1999; 33: 1506-1511.
79. Perondi R., Saino A., Tio R. A. et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease. Circulation 1992; 85: 2004-2013.
80. Scherrer U., Sartori C. Insulin as a vascular and sympathoexcitatory hormone: Implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104-4113.
81. Lembo G., Iaccarino G., Rendina V., Volpe M., Trimarco B. Insulin blunts sympathetic vasoconstriction through the α 2-adrenergic pathway in humans. Hypertension 1994; 24: 429-438.
82. Eliasson B., Attvall S., Taskinen M.-R., Smith U. Smoking cessation improves insulin sensitivity in healthy middle-aged men. Eur J Clin Invest 1997; 27: 450-456.
83. Mayer-Davis E. J., D'Agostino R., Jr., Karter A. J. et al. Intensity and amount of physical activity in relation to insulin sensitivity: The insulin resistance atherosclerosis study. JAMA 1998; 279: 669-674.
84. Shinozaki K., Suzuki M., Ikebuchi M. et al. Insulin resistance associated with compensatory hyperinsulinemia as an independent risk factor for vasospastic angina. Circulation 1995; 92: 1749-1757.
85. Suzuki M., Shinozaki K., Kanazawa A. et al. Insulin resistance as an independent risk factor for carotid wall thickening. Hypertension 1996; 28: 593-598.
86. Horrobin D. F. A new concept of lifestyle-related cardiovascular disease: The Importance of interactions between cholesterol, essential fatty acids, prostaglandin E1 and thromboxane A2. Med Hypotheses 1980; 6: 785-800.
87. Makita K., Falck J. R., Capdevila J. H. Cytochrome P450, the arachidonic acid cascade, and hypertension: New vistas for an old enzyme system. FASEB J 1996; 10: 1456-1463.
88. Holla V. R., Adas F., Imig J. D. et al. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Natl Acad Sci USA 2001; 98: 5211-5216.
89. Iber H., Li-Masters T., Chen Q., Yu S., Morgan E. T. Regulation of hepatic cytochrome P450 2C11 via cAMP: Implications for down-regulation in diabetes, fasting, and inflammation. J Pharmacol Exp Ther 2001; 297: 174-180.
90. Galal A., Souich P. 21-aminosteroids prevent the down-regulation of hepatic cytochrome P450 induced by hypoxia and inflammation in conscious rabbits. Br J Pharmacol 1999; 128: 374-379.
91. Morgan E. T. Regulation of cytochrome P450 by inflammatory mediators: Why and how?. Drug Metab Dispos 2001; 29: 207-212.
92. Yang B., Graham L., Dikalov S. et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxiareoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001; 60: 310-320.
93. Hall E., Hylemon P., Vlahcevic Z. et al. Overexpression of CYP27 in hepatic and extrahepatic cells: Role in the regulation of cholesterol homeostasis. Am J Physiol 2001; 281: G293-G301.
94. Jefcoate C. R., Liehr J. G., Santen R. J. et al. Tissue-specific synthesis and oxidative metabolism of estrogens. Monogr Natl Cancer Inst 2000: 95-112.
95. Ghosh M. K., Mukhopadhyay M., Chatterjee I. B. NADPH-initiated cytochrome P450-dependent free iron-independent microsomal lipid peroxidation: Specific prevention by ascorbic acid. Mol Cell Biochem 1997; 166: 35-44.
96. Omdahl J. L., Bobrovnikova E. A., Choe S., Dwivedi P. P., May B. K. Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway. Steroids 2001; 66: 381-389.
97. Chen H. W., Lii C. K., Sung W. C., Ko Y. J. Effect of vitamin E on rat hepatic cytochrome P-450 activity. Nutr Cancer 1998; 31: 178-183.
98. Doostdar H., Burke M. D., Mayer R. T. Bioflavonoids: Selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000; 144: 31-38.
99. Ting H. H., Timimi F. K., Haley E. A., Roddy M.-A., Ganz P., Creager M. A. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95: 2617-2622.
100. Hopkins P. N., Williams R. R. A survey of 246 suggested coronary risk factors. Atherosclerosis 1981; 40: 1-52.
101. Hellstrom H. R. Cholesterol, an important but relatively overemphasized risk factor for ischemic heart disease. Med Hypotheses 2001; 57: 593-601.
102. LaRosa J. C., He J., Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
103. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154-160.
104. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
105. Rosenson R. S., Tangney C. C. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-1650.
106. O'Driscoll G., Green D., Taylor R. R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within one month. Circulation 1997; 95: 1126-1131.
107. Ridker P. M., Rifai N., Pfeffer M. A. et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-844.
108. Vaughan C. J., Gotto A. M., Jr., Basson C. T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
109. Mundy G., Garrett R., Harris S. et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949.
110. Meier C. R., Schlienger R. G., Kraenzlin M. E., Schlegel B., Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210.
111. Freeman D. J., Norrie J., Sattar N. et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
112. Jick H., Zornberg G. L., Jick S. S., Seshadri S., Drachman D. A. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
113. Mostaza J. M., Gomez M. V., Gallardo F. et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000; 35: 76-82.
114. de Lorgeril M., Salen P., Martin J.-L., Monjaud I., Delaye J., Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.
115. Califf R. M., Armstrong P. W., Carver J. R., D'Agostino R. B., Sr., Strauss W. E. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5: stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol 1996; 27: 964-1047.
116. Wilson P. W. F., D'Agostino R. B., Levy D., Belanger A. M., Silbershatz H., Kannel W. B. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
117. Diaz M. N., Frei B., Vita J. A., Keaney J. F. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337: 408-416.
118. Forrester J. S. Merz N. B., Bush T. L. et al. 27th Bethesda Conference: Matching the Intensity of Risk Factor Management With the Hazard for Coronary Disease Events. Task Force 4: Efficacy of risk factor management. J Am Coll Cardiol 1996; 27: 964-1047.
119. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.
120. LaRosa J. C. Prevention and treatment of coronary heart disease: Who benefits?. Circulation 2001; 104: 1688-1692.
121. Schwed A., Fallab C. L., Burnier M. et al. Electronic monitoring of compliance to lipid-lowering therapy in clinical practice. J Clin Pharmacol 1999; 39: 402-409.
122. Sacks F. M., Pfeffer M. A., Moye L. A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
123. Albert M. A., Staggers J., Chew P. The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design. Am Heart J 2001; 141: 893-898.
124. The Bezafibrate Infarction Prevention (BIP) Study Group I. Lipids and lipoproteins in symptomatic coronary heart disease: Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. Circulation 1992; 86: 839-848.
125. Ginsburg G. S., Safran C., Pasternak R. G. Frequency of low serum high-density lipoprotein cholesterol levels in hospitalized patients with 'desirable' total cholesterol levels. Am J Cardiol 1991; 68: 187-192.
126. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-1445.
127. Chang K. Diet and exercise are found to cut diabetes by over half. New York Times. August 9, 2001. p. A1 (National edition), p. A16 (Local edition).
128. NIH/NHLBI News Release. NCEP Issues Major New Cholesterol Guidelines. (Available at http://nhlbi.nih.gov/press/01-05-15.htm.).
129. Aoki N. Drug Makers' Influence Pondered Eye on US Advice to Cut Cholesterol. The Boston Globe, May 31, 2002. p. A1.
130. Neel J. V. Diabetes mellitus: A 'thrifty' genotype rendered detrimental by 'progress'? Am J Hum Genet 1962; 14: 353-362.
131. Cordain L., Gotshall R. W., Eaton S. B., Eaton S. B. I. Physical activity, energy expenditure and fimess: An evolutionary perspective. Int J Sports Med 1998; 19: 328-335.
132. Eaton S. B., Cordain L. Evolutionary aspects of diet: Old genes, new fuels: Nutritional changes since agriculture. World Rev Nutr Diet 1997; 81: 26-37.
133. Eaton S. B., Eaton S. B. I., Sinclair A. J., Cordain L., Mann N. J. Dietary intake of long-chain polyunsaturated fatty acids during the paleolithic. Wold Rev Nutr Diet 1998; 83: 12-23.
134. Cordain L. Cereal grains: Humanity's double-edged sword. World Rev Nutr Diet 1999; 84: 19-73.
135. Kris-Etherton P. M., Yu-Poth S., Sabaté J., Ratcliffe H. E., Zhao G., Etherton T. D. Nuts and their bioactive constituents: Effects on serum lipids and other factors that affect disease risk. Am J Clin Nutr 1999; 70(suppl.): 504S-511S.
136. Fernández-Real J.-M., Ricart W. Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999; 42: 1367-1374.
137. O'Keefe J. H., Wetzel M., Moe R. R., Bronsnahan K., Lavie C. J. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?. J Am Coll Cardiol 2001; 37: 1-8.
138. Mital S., Zhang X., Zhao G. et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol 2000; 279: H2649-H2657.
139. Kaesemeyer W. H., Caldwell R. B., Huang J., Caldwell R. W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 1999; 33: 234-241.
140. Vogel R. A., Corretti M. C., Plotnick G. D. The postprandial effect of components of the Mediterranean diet on endothelial function. J Am Coll Cardiol 2000; 36: 1455-1460.
141. Keaney J. F., Jr., Simon D. I., Freedman J. E. Vitamin E and vascular homeostasis: Implications for atherosclerosis. FASEB J 1999; 13: 965-975.
142. Tribble D. L. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and β-carotene: A statement for healthcare professionals from the American Heart Association. Circulation 1999; 99: 591-595.
143. Kuller L. H. A time to stop prescribing antioxidant vitamins to prevent and treat heart disease? Arterioscler Thromb Vasc Biol 2001; 21: 1253.
144. Tzemos N., Lim P. O., MacDonald T. M. Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized, double-blind, crossover study. Circulation 2001; 104: 511-514.
145. von der Leyen H. E., Dzau V. J. Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 2001; 103: 2760-2765.